Allergan Defends 3-Month Exclusivity Deal For Namenda
By John Kennedy · March 17, 2017, 6:48 PM EDT
Pharmaceutical patent holders that sue generic-drug manufacturers for infringement and then shorten product exclusivity periods via settlements shouldn't have to actually win those cases to maintain exclusivity, an Allergan unit told...
To view the full article, register now.